Atlas Trials

PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients

Clinical trial NCT03029858 · UNKNOWN

Trial details

NCT number
NCT03029858
Sponsor
Guangdong Association of Clinical Trials
Status
UNKNOWN
Study type
OBSERVATIONAL
Small Cell Lung Cancer, Polygonal Type
Start date
2017-01-01
Primary completion
2020-09-01
Enrollment
155

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.